Efficacy and safety of NT 201 for upper limb spasticity of various etiologies - A randomized parallel-group study

Acta Neurologica Scandinavica

Volumn 122, Issue 4, 2010, Pages 295-302

  Barnes, M ^a   Schnitzler, A ^b   Medeiros, L ^c   Aguilar, M ^d   Lehnert Batar, A ^e   Minnasch, P ^e  

^a Service de Médecine Physique et Réadaptation ^*  (United Kingdom)

^b RAYMOND POINCARÉ HOSPITAL   (France)

^c Hospital Mútua de Terrassa ^*  (Portugal)

^d HOSPITAL MÚTUA DE TERRASSA   (Spain)

^e MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

botulinum neurotoxin type A; etiology; functional disability; muscle tone; NT 201; upper limb spasticity; Xeomin

Indexed keywords

BOTULINUM TOXIN A;

ADULT; ARM; ARTICLE; BRAIN INJURY; CEREBRAL PALSY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DILUTION; DISABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HEMATOMA; HUMAN; INJECTION SITE PAIN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MUSCLE TONE; MUSCLE WEAKNESS; NAUSEA; RANDOMIZED CONTROLLED TRIAL; SPASTICITY; STROKE; TREATMENT RESPONSE;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; BRAIN INJURIES; CEREBRAL PALSY; FEMALE; HEMATOMA; HUMANS; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; MUSCLE SPASTICITY; MUSCLE WEAKNESS; PROSPECTIVE STUDIES; STROKE; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 77956405659     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2010.01354.x     Document Type: Article

References (19)

1. Elia AE, Graziella F, Albanese A. Clinical trials of botulinum toxin in adult spasticity. In : Jankovic J, Albanese A, Atassi MZ, Dolly JO, Hallet M, Mayer NH, eds. Botulinum toxin - therapeutic clinical practice and science, 1st edn. New York, USA : Saunders Elsevier, 2009 148 158.
2. Simpson DM, Gracies J-M, Graham HK, et al. Assessment: botulinum neurotoxin for the treatment of spasticity (an evidence-based review). Report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology 2008 70 : 1691 1698.
3. Wissel J, Ward AB, Erztgaard P, et al. European consensus table on the use of botulinum toxin type A in adult spasticity. J Rehabil Med 2009 41 : 13 25.
4. Jost WH, Kohl A, Brinkmann S, Comes G. Efficacy and tolerability of a botulinum toxin type A free of complexing proteins (NT 201) compared with commercially available botulinum toxin type A (BOTOX®) in healthy volunteers. J Neural Transm 2005 112 : 905 913.
5. Wohlfarth K, Müller C, Sassin I, Comes G, Grafe S. Neurophysiological double-blind trial of a botulinum neurotoxin type A free of complexing proteins. Clin Neuropharmacol 2007 30 : 86 94. (Pubitemid 46581201)
6. Benecke R, Jost WH, Kanovsky P, Ruzicka E, Comes G, Grafe S. A new botulinum toxin type A free of complexing proteins for treatment of cervical dystonia. Neurology 2005 64 : 1949 1951.
7. Roggenkämper P, Jost WH, Bihari K, Comes G, Grafe S. Efficacy and safety of a new botulinum toxin type A free of complexing proteins in the treatment of blepharospasm. J Neural Transm 2006 113 : 303 312.
8. Kañovský P, Slawek J, Denes Z, et al. Efficacy and safety of botulinum neurotoxin NT 201 in post-stroke upper limb spasticity. Clin Neuropharmacol 2009 32 : 259 265.
9. Ashworth B. Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964 192 : 540 542.
10. Brashear A, Zafonte R, Corcoran M, et al. Inter- and intra-rater reliability of the Ashworth scale and the Disability Assessment Scale in patients with upper-limb poststroke spasticity. Arch Phys Med Rehabil 2002 83 : 1349 1354.
11. WE MOVE. BTX-A (BOTOX®) Adult dosing guidelines for the management of spasticity. Aug 2005. Available at: http://www.mdvu.org/library/dosingtables/. Accessed September 2005.
12. Jost WH, Blümel J, Grafe S. Botulinum neurotoxin type A free of complexing proteins (XEOMIN®) in focal dystonia. Drugs 2007 67 : 669 683. (Pubitemid 46535642)
13. Brashear A, Gordon MF, Elovic E, et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Engl J Med 2002 347 : 395 400.
14. Elia AE, Filippini G, Calandrella D, Albanese A. Botulinum neurotoxins for post-stroke spasticity in adults: a systematic review. Mov Disord 2009 24 : 801 812.
15. Brashear A, Mcafee AL, Kuhn ER, Fyffe J. Botulinum toxin type B in upper-limb poststroke spasticity: a double-blind, placebo-controlled trial. Arch Phys Med Rehabil 2004 85 : 705 709. (Pubitemid 38857904)
16. Elovic EP, Brashear A, Kaelin D, et al. Repeated treatments with botulinum toxin type A produce sustained decreases in the limitations associated with focal upper-limb poststroke spasticity for caregivers and patients. Arch Phys Med Rehabil 2008 89 : 799 806.
17. Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil 2002 81 : 355 363.
18. Gracies JM, Lugassy M, Weisz DJ, Vecchio M, Flanagan S, Simpson DM. Botulinum toxin dilution and endplate targeting in spasticity: a double-blind controlled study. Arch Phys Med Rehabil 2009 90 : 9 16.
19. Turkel CC, Bowen B, Liu J, Brin MF. Pooled analysis of the safety of botulinum toxin type A in the treatment of poststroke spasticity. Arch Phys Med Rehabil 2006 87 : 786 792.